Norway pharmacy online: Kjøp av viagra uten resept i Norge på nett.

Jeg har selv prøvd dette kamagra Det er billig og fungerer egentlig, jeg likte det) kjøp kamagra Ikke prøvd, men du kan eksperimentere med... Hvordan føler du deg, følsomhet etter konsumere piller?.

Master ics guidelines all sections.pdf

Guidelines for Adult Organ and Tissue Donation
Prepared on behalf of the Intensive Care Society by the Society’s Working Group on
Organ and Tissue Donation (November 2004)
Chapter 5 - Clinical management of the potential heartbeating organ donor

5. Clinical management of the potential heart beating organ donor

Pathophysiological Changes after Brain Stem Death
Widespread changes occur after brain stem death, which may jeopardise the function of potentially transplantable organs (Table 1). Table 1. Approximate incidence of pathophysiological changes after brain stem death (%). 5.1.1 Cardiovascular changes There are usually two distinct phases, characterised by sympathetic overactivity and underactivity. The first phase is not seen in all patients. Hyperdynamic phase: Sympathetic overactivity causes a transient
catecholamine surge, (particularly adrenaline and noradrenaline) which
increases in heart rate, blood pressure, cardiac output and systemic vascular
resistance. The catecholamine storm adversely affects the delicate balance
between myocardial oxygen supply and demand.
Cardiovascular collapse phase (Table 2): Hypotension results from loss of
sympathetic tone, profound vasodilatation and myocardial depression.
Hypovolaemia secondary to diabetes insipidus (5.1.2) frequently contributes to
hypotension in unsupported patients with brain stem death.
Table 2. Causes of cardiovascular collapse after brain stem death. Subendocardial myocardial ischaemia and ventricular dysfunction are common even in previously healthy hearts. Blood gas and electrolyte disturbances may also contribute to the ECG abnormalities which include ST segment and T wave changes, arrhythmias and conduction abnormalities. Most changes are usually temporary and reversible. 5.1.2 Endocrine changes Anterior and posterior pituitary failure causes significant reductions in the circulating levels
of tri-iodothyroni ne (T3) and thyroxine (T4). The former may contribute to cardiovascular
deterioration. Reduced production of anti-diuretic hormone (ADH) causes diabetes
insipidus (DI) which occurs in up to 65% of organ donors. It is characterised by diuresis,
hypovolaemia, plasma hyperosmolality and hypernatraemia. Reductions in cortisol
production are unrelated to the degree of hypotension but may impair donor stress
Insulin secretion is reduced and contributes to the development of hyperglycaemia. This
may be aggravated by the administration of large volumes of glucose containing fluids, if
used to treat hypernatraemia and increased levels of catecholamines. Untreated
hyperglycaemia leads to increased extracellular osmolality, metabolic acidosis, osmotic
diuresis and cardiovascular instability.
5.1.3 Pulmonary changes
Pulmonary dysfunction is common in the organ donor and may be due to the development
of pneumonia, aspiration of gastric contents, neurogenic pulmonary oedema or pulmonary
5.1.4 Coagulopathy
Haemostatic disorders may occur secondary to release of tissue thromboplastin by
ischaemic or necrotic brain. Disseminated intravascular coagulation is common and its
incidence increases with the duration of brain stem death.
5.1.5 Hypothermia
Hypothalamic failure after brain stem death results in impairment of temperature
regulation. Heat production is reduced because of a fall in metabolic rate and loss of
muscular activity. This is associated with an increase in heat loss because of peripheral
vasodilatation. Active measures may be required to prevent hypothermia.
The clinical course of a ventilated but otherwise unsupported brain stem dead patient is
short with asystolic cardiac arrest generally occurring within 72 hours. However cardiac
and other body functions have been maintained for many days in fully supported brain
dead patients.
5.2 Resuscitation and Maintenance of the Organ Donor
Following the certification of death by brain stem testing and the lack of objection to
donation, there is a change in the emphasis of care. Therapy previously aimed at
preserving brain function is now directed at optimising transplantable organ function. There
is no decrease in patient dependency because the need for therapeutic intervention and
support of relatives continues. Adequate time must be allowed for confirmation of brain
stem death but unnecessary delays should be avoided to minimise the risk of deterioration
of the donor. High quality critical care including chest physiotherapy, aseptic precautions
and antibiotics may be required. The patient has usually been rendered slightly
hypovolaemic by brain protecting therapies. Although hypovolaemia should be corrected,
it is important to avoid excessive volume replacement particularly in potential lung and
heart donors. The primary goals are maintenance of adequate tissue perfusion and
preservation of organ viability.
5.3 Monitoring the Organ Donor
Optimal haemodynamic management requires invasive monitoring. Because of the order
in which the great vessels are ligated during the donor operation, any newly placed arterial
cannula should be inserted into the left radial or brachial artery. Equally a new central
venous or pulmonary artery catheter (PAC) should be inserted into the right internal jugular
or subclavian veins.
Intravenous fluid administration must be carefully monitored as organs, particularly the
lungs, which may have been damaged during the period of sympathetic hyperactivity, are
susceptible to volume overload and capillary leakage.
Echocardiography is useful to exclude major structural abnormalities of the heart and to
measure left ventricular ejection fraction. Some transplant units will only request insertion
of a PAC in those patients estimated to have a left ventricular ejection fraction below
Transthoracic echocardiography (TTE) may be technically difficult and better images may
be obtained with transoesophageal echocardiography (TOE). Transient regional wall
motion abnormalities are common and systolic inward motion and thickening may improve
with haemodynamic optimisation. Assessment of right ventricular size and function is
important and frequently challenging.
5.4 Supporting the Organ Donor
5.4.1 Cardiovascular support
The goals of haemodynamic management are to optimise cardiac output maintaining
normal preload and afterload. Where possible, the use of high dose ß adrenoreceptor
agonists, other inotropes and vasopressors, which increase myocardial oxygen demand
and deplete myocardial high energy phosphates should be avoided.
The following haemodynamic goals are generally appropriate in potential adult heart
donors (Table 3).
Table 3. Appropriate haemodynamic goals for potential adult heart donors.
Pulmonary artery occlusion pressure ~ 10-15 mmHg
Patients who do not achieve these goals may still be considered for donation of other
organs. These goals can usually be achieved by the standard critical care therapies (Table
Table 4. Principles of critical care management for adult heart donation
The choice of inotropic support varies between transplant units and may be guided by data from pulmonary artery catheterisation but: • High dose adrenaline may result in detrimental vasoconstriction in donor • The vasodilator effects of dobutamine may lead to undesirable hypotension • Vasopressin is less likely to cause metabolic acidosis or pulmonary hypertension and may be a more appropriate than noradrenaline for the cardiovascular collapse phase. 5.4.2 Endocrine support Hormone replacement therapy may reduce inotrope requirements and should be considered in all organ donors2. The therapies used to correct the common endocrine disturbances are shown in Table 5. Table 5. The common endocrine problems seen in HBDs. Maintain Na+ = 155 mmol.l-1 with 5% dextrose3 Maintain urine output about 1 - 2 -1 with vasopressin (pitressin) 1 U bolus and 0.5-4.0 U.h-1 infusion1. If vasopressin fails to control diuresis, intermittent desmopressin (DDAVP) may occasionally be required. Insulin infusion to maintain plasma glucose 4-9 mmol.l-1 Tri-iodothyronine (T3) 4 µg bolus then infusion at 3 µg.h-1 Debate continues over the value of T3 replacement. Practical difficulties identifying the subgroup of patients with decreased free T3 have led to most transplant units empirically commencing T3 infusions in all potential organ donors. High dose methylprednisolone 15 is commonly given as part of the hormone package to diminish the inflammatory response. If the lungs are to be transplanted, the FiO2 should be kept at or below 0.4 to minimise the risks of oxygen toxicity. A modest level of positive end expiratory pressure (PEEP) (i.e. <5 cmH2O) will prevent alveolar collapse. Strict asepsis should be continued during physiotherapy and tracheal toilet. Physiotherapy should include hourly gentle inflation of the lungs and two hourly side-to-side turning. The transplant team may request an up to date chest X-ray. Suitable goals for respiratory support are: • maintenance of normocapnia (PaCO2 ~ 5.0-5.5 kPa). • ventilation with the lowest FiO2 to maintain PaO2 of >10.0 kPa. • PEEP > 5 cmH2O may reduce cardiac output and is rarely required. • high inspiratory pressures should be avoided. The mode of ventilation needs to be carefully selected: • consider pressure control ventilation. • modes that allow patient triggered ventilation are not appropriate. • Very sensitive ventilatory triggers may allow cardiac cycle induced pressure changes to trigger the ventilator. This may cause diagnostic confusion by giving the appearance of a spontaneous breath. 5.4.4 Renal support Hypotension is associated with acute tubular necrosis and failure of transplanted kidneys. Although low dose dopamine is now unfashionable in the general critical care setting, there is some evidence that donor pre-conditioning with dopamine improves initial graft function after kidney transplantation4. 5.4.5 Haematological support The haemoglobin concentration should be maintained over 9 gm.dl-1. Deranged coagulation should be treated with fresh frozen plasma and platelets. Antifibrinolytics such as epsilon aminocaproic acid may cause microvascular thrombi in donor organs and should be avoided. 5.4.6 Temperature support Hypothermia should be anticipated and heat loss prevented by using: • heated and humidified inspired gases
5.5 Nursing and Psychological Care
Nursing staff working in critical care areas play a key role in caring for potential organ
donors and their families. The complex care required by these patients and families has
been described as emotionally demanding and stressful5-7. The donor’s family, friends and
carers will require considerable psychological and pastoral support8. The circumstances
of the donor’s death may engender feelings of remorse guilt or anger. Nurses may have
difficulty caring for a patient in whom death has been declared when, previously, care was
directed at saving life. Explaining futility of care to families and friends is difficult. The
attitudes and actions of nursing staff will significantly affect the family5-7. Therefore it is
necessary for critical care units to ensure that nurses caring for these patients have a
sound knowledge of:
• Organ/tissue donation, transplantation and ethical issues. • The diagnosis of death by brain stem testing and its certification. • The continued clinical management of the potential organ donor. • The ability to support families during a stressful time. • Awareness of religious and cultural issues with regard to organ/tissue donation. • The role of donor transplant co-ordinators. These educational elements should be included in local orientation and on going competency training in critical care. Designating an experienced ‘Link Nurse’ in the critical care unit, to liaise with the donor liaison nurse and donor transplant co-ordinator will assist in the delivery of such education and updates of any practice changes9-11. Donor transplant co-ordinators and donor liaison nurses can also support staff in debriefing and reviewing any aspects of individual donations6,10. Important aspects of medical and nursing care that must be continued are described above; these will require careful explanation to families. As well as continuing to care for the patient, nursing staff will also help families understand the necessity for: • Adherence to infection control procedures. • Hygiene needs as required as individual to the patient.
Relatives of potential organ donors report that they derive great comfort in seeing staff
maintain care and respect for their dead relative as if they were alive8,11,12.
Effective documentation and communication between medical and nursing staff is vital to
ensure the families of organ donors are supported and kept well informed of the progress
of events.
Staffing levels and skill mix may need to be reviewed to ensure experienced critical care
nurses are available to care for the potential organ donor and their family. All aspects of
care will require the full attention of a trained nurse even if the patient’s physical needs are
minimal, as more nursing time will be required for the family’s ongoing support,
explanations and discussions.
Further details about managing organ donation will be described in the UK Transplant
Donor Management Guidelines which will be available in early 2005, and will be placed on
the website
Zaroff JG, Rosengard BR, Armstrong WF et al. Consensus conference report: maximizing use of organs recovered from the cadaver donor: cardiac recommendations, March 28-29, 2001, Crystal City, Va. Circulation 2002; 106: 836-41. Rosendale JD, Kauffman HM, McBride MA et al. Hormonal resuscitation yields more transplanted hearts, with improved early function. Transplantation 2003; 27: 1336-41. Totsuka E, Dodson F, Urakami A et al. Influence of high donor serum sodium levels on early postoperative graft function in human liver transplantation: effect of correction of donor hypernatremia. Liver Transplantation and Surgery 1999; 5: 421-8. Schnuelle P, Yard BA, Braun C et al. Impact of donor dopamine on immediate graft function after kidney transplantation. American Journal of Transplantation 2004; 4: 419-26 Hibbert M. Stressors experienced by nurses while caring for organ donors and their families. Heart and Lung 1995; 24: 399-407. Pearson A, Robertson-Malt S, Walsh K. Intensive care nurses’ experience of caring for brain dead organ donor patients. Journal of Clinical Nursing 2001; 10: 132–9. Pelletier-Hibbert M. Coping strategies used by nurses to deal with the care of organ donors and their families. Heart and Lung 1998; 27: 230-7. Riley LP, Coolican BM. Needs of families of organ donors: facing death and life. Critical Care Nurse 1999; 19: 53-9. Watkinson GE. A study of the perception and experience of critical care nurses in caring for potential and actual donors: implications for nurse education. Journal of Advanced Nursing 1995; 22: 929-40. Randhawa G. Specialist nurse training programme: dealing with asking for organ donation. Journal of Advanced Nursing 1998; 28: 405-8. Coyle MA. Meeting the needs of the family: the role of the specialist nurse in the management of brain death. Intensive and Critical Care Nursing 2000;16: 45-50. Seymour JE. Critical Moments – Death and Dying in Intensive Care. Buckingham: Open University Press, 2001.


Report vote q4 consolidated_ntr2

Vote Performance Report Vote: 166 Hoima Referral Hospital Structure of Submission QUARTER 4 Performance Report Summary of Vote Performance Cumulative Progress Report for Projects and Programme Quarterly Progress Report for Projects and Programmes Submission Checklist Vote Performance Report Vote: 166 Hoima Referral Hospital QUARTER 4: Highlights of Vote Performance

Der mdr1-defekt

Der MDR1-Defekt eine kleine Zusammenfassung des Seminars am 22.10.2005 unter Leitung von Dr. Joachim M. Geyer,Dipl. oec. troph. Barbara Döring und Josè R. Godoy Berthet. MDR ist die Abkürzung für „Multi Drug Resistance“. Das MDR1-Gen ist zuständig für die Bildung von P-glycoprotein (P-gp). P-gp wird benötigtfür den Membrantransport von Arzneistoffen (oder anderen Substanzen). Um di

Copyright © 2010-2014 Drug Shortages pdf